Myasthenia gravis - causes, symptoms, treatment, pathology

Summary

Myasthenia gravis is an autoimmune disorder characterized by muscle weakness, particularly affecting the skeletal muscles. It leads to symptoms like progressive weakness throughout the day, double vision, and drooping eyelids. The condition predominantly impacts young women and older men, with an unclear cause for this age distribution. The disease is a type II hypersensitivity, where autoantibodies target acetylcholine receptors on muscle cells, hindering muscle contraction signals. Treatment includes acetylcholinesterase inhibitors to increase acetylcholine levels, immunosuppressive drugs to reduce antibody production, and thymus removal. This informative script sheds light on the mechanisms and management of myasthenia gravis.

Takeaways

• 💊 Myasthenia gravis is an autoimmune disease that causes muscle weakness, particularly affecting skeletal muscles.
• 🌞 Patients might experience fluctuating strength levels throughout the day, with symptoms worsening as the day progresses.
• 👁️ Myasthenia gravis can impact the extraocular muscles, leading to double vision (diplopia) and drooping eyelids (ptosis).
• 👧👴 The disease has a bimodal age distribution, predominantly affecting young women in their 20s and 30s and older men in their 60s and 70s.
• 🔬 In a normal muscle contraction, motor neurons release acetylcholine, which binds to receptors on muscle cells, triggering a chain reaction for muscle movement.
• 🛡️ Myasthenia gravis is a type II hypersensitivity disorder where autoantibodies target and damage host cells, specifically the nicotinic acetylcholine receptors on muscle cells.
• 🚫 Antibodies in myasthenia gravis prevent acetylcholine from binding to its receptors, blocking the muscle contraction signal from the nervous system.
• 🔄 The complement system, activated by the antibodies, causes inflammation and destruction of muscle cells, further reducing acetylcholine receptor availability.
• 🏥 Some patients produce muscle-specific receptor tyrosine kinase antibodies, which attack internal muscle cell proteins, leading to cell destruction.
• ⚠️ In rare cases, myasthenia gravis can be a paraneoplastic syndrome, associated with underlying cancers that trigger autoantibody production.
• 💊 Treatment options for myasthenia gravis include acetylcholinesterase inhibitors, immunosuppressive drugs, and surgical thymus removal to alleviate symptoms.

Q & A

What is the literal meaning of 'Myasthenia gravis'?

Myasthenia gravis is a Latin expression that literally means 'grave muscle weakness', which describes the severe muscle weakness associated with this condition.

How does myasthenia gravis affect the skeletal muscles?

Myasthenia gravis is an autoimmune disease that affects the skeletal muscles, causing them to become progressively weaker throughout the day, especially with repetitive movements.

What are the symptoms related to the extraocular muscles in myasthenia gravis?

Myasthenia gravis can affect the extraocular muscles, leading to symptoms such as diplopia (double vision) and ptosis (drooping eyelids).

Which age groups are predominantly affected by myasthenia gravis?

Myasthenia gravis preferentially affects young women in their 20s and 30s, and older men in their 60s and 70s.

What is the normal process of muscle contraction at the cellular level?

Normal muscle contraction involves motor neurons releasing acetylcholine at the neuromuscular junction, which binds to nicotinic acetylcholine receptors on muscle cell membranes, triggering a chain reaction that results in muscle contraction.

How does myasthenia gravis interfere with the normal muscle contraction process?

In myasthenia gravis, the patient's B cells produce antibodies that bind to and block the nicotinic acetylcholine receptors, preventing the muscle cells from responding to the 'contract' signal from the central nervous system.

What is the role of the complement system in myasthenia gravis?

The complement system, a family of small proteins that fight off bacterial infections, is activated by anti-acetylcholine receptor antibodies in myasthenia gravis, causing inflammation and destruction of muscle cells and reducing the number of acetylcholine receptors.

What are muscle specific receptor tyrosine kinase antibodies, and how do they affect myasthenia gravis?

Muscle specific receptor tyrosine kinase antibodies are another type of harmful antibody found in a minority of people with myasthenia gravis. They attack proteins inside muscle cells, leading to the destruction of healthy cells.

Can myasthenia gravis be related to an underlying cancer?

In very rare cases, myasthenia gravis can present as a paraneoplastic syndrome, where an underlying cancer generates an immune response that results in the production of autoantibodies.

What is a myasthenic crisis, and how can it be life-threatening?

A myasthenic crisis is a life-threatening manifestation of myasthenia gravis where certain muscles, such as those controlling breathing, experience decreased function, potentially leading to respiratory failure.

What are some treatments for myasthenia gravis?

Treatments for myasthenia gravis include acetylcholinesterase inhibitors like neostigmine or pyridostigmine to increase acetylcholine concentration, immunosuppressive drugs like prednisone to reduce harmful antibody production, and surgical removal of the thymus.

Why is the removal of the thymus beneficial in treating myasthenia gravis?

The removal of the thymus, even in the absence of identifiable thymus gland problems, can reduce muscle weakness symptoms in myasthenia gravis, possibly because helper T cells that originate in the thymus aid B cells in making antibodies to the acetylcholine receptor.

Outlines

00:00

💊 Understanding Myasthenia Gravis: Autoimmune Attack on Muscles

Myasthenia gravis is an autoimmune disease characterized by fluctuating muscle weakness, particularly affecting skeletal muscles. It can lead to symptoms such as progressive daily weakness, double vision (diplopia), and drooping eyelids (ptosis) due to the impact on extraocular muscles. The condition has a 'bimodal' age-of-onset distribution, predominantly affecting young women and older men, although the cause remains unclear. The disease process involves the production of autoantibodies that target nicotinic acetylcholine receptors at the neuromuscular junction, impairing muscle contraction signals. These antibodies can also trigger the complement system, causing inflammation and destruction of muscle cells. In rare cases, myasthenia gravis can be associated with other harmful antibodies or paraneoplastic syndromes related to underlying cancers. Treatment strategies include acetylcholinesterase inhibitors to increase acetylcholine levels, immunosuppressive drugs to reduce antibody production, and surgical thymus removal, which may help by affecting the immune response.

05:04

📢 Supporting Myasthenia Gravis Education and Awareness

This paragraph serves as a call to action for viewers to support the educational efforts on myasthenia gravis. It encourages donations on Patreon, subscribing to the channel, or following on social media to stay informed and contribute to the spread of awareness about this autoimmune disorder. The paragraph emphasizes the importance of community engagement and support in understanding and managing myasthenia gravis.

Keywords

💡Myasthenia Gravis

Myasthenia gravis is an autoimmune disease characterized by muscle weakness. It is the central theme of the video, as it discusses the symptoms, causes, and treatments related to this condition. The term 'myasthenia gravis' is derived from Latin, meaning 'grave muscle weakness,' which is exemplified in the script by describing the progressive muscle weakness experienced by patients throughout the day.

💡Autoimmune Disease

An autoimmune disease is a condition where the immune system mistakenly attacks the body's own tissues. In the context of the video, myasthenia gravis is classified as an autoimmune disease, specifically a type II hypersensitivity, where the body produces antibodies that target its own cells or proteins, leading to muscle weakness and other symptoms.

💡Neuromuscular Junction

The neuromuscular junction is the connection point between a motor neuron and a muscle fiber, where the neuron releases a neurotransmitter to stimulate muscle contraction. The video explains the normal functioning of this junction, emphasizing the role of acetylcholine in binding to receptors on muscle cell membranes, which is disrupted in myasthenia gravis due to the presence of autoantibodies.

💡Acetylcholine

Acetylcholine is a neurotransmitter that plays a crucial role in muscle contraction. As described in the video, motor neurons release acetylcholine at the neuromuscular junction, which binds to receptors on muscle cells, triggering a chain reaction that results in muscle contraction. In myasthenia gravis, the binding of acetylcholine is impeded by autoantibodies, leading to muscle weakness.

💡Nicotinic Acetylcholine Receptors

Nicotinic acetylcholine receptors are protein structures found on muscle cell membranes that bind to acetylcholine, initiating muscle contraction. The video highlights that in myasthenia gravis, these receptors are targeted by autoantibodies produced by the patient's immune system, which prevents acetylcholine from binding and thus hampers muscle function.

💡Type II Hypersensitivity

Type II hypersensitivity refers to an immune response where antibodies are produced against the body's own cells, leading to cytotoxic injury and cell death. The video explains that myasthenia gravis is categorized under this type of hypersensitivity, where autoantibodies target the nicotinic acetylcholine receptors, causing the destruction of these receptors and impairing muscle function.

💡Complement System

The complement system is a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells, promoting inflammation and attacking the pathogen's cell membrane. The video mentions that the activation of the complement system by anti-acetylcholine receptor antibodies leads to inflammation and destruction of muscle cells in myasthenia gravis.

💡Muscle Specific Receptor Tyrosine Kinase Antibodies

These are a type of harmful antibody that some individuals with myasthenia gravis produce. Unlike the antibodies that target the nicotinic acetylcholine receptors, muscle specific receptor tyrosine kinase antibodies attack proteins inside muscle cells. The video notes that this leads to the destruction of healthy cells, contributing to the muscle weakness associated with the disease.

💡Paraneoplastic Syndrome

Paraneoplastic syndrome refers to a group of symptoms that result from the body's immune response to an underlying cancer, rather than from the cancer itself. The video explains that in rare cases, myasthenia gravis can present as a paraneoplastic syndrome, where an immune response to cancers like bronchogenic carcinoma or thymic neoplasm results in the generation of autoantibodies.

💡Myasthenic Crisis

A myasthenic crisis is a severe and potentially life-threatening exacerbation of myasthenia gravis, often characterized by respiratory failure due to weakened breathing muscles. The video describes this as a serious manifestation of the disease, where affected muscles, such as those controlling breathing, can lead to a medical emergency.

💡Thymus

The thymus is a gland located in the chest that plays a critical role in the development of T cells, which are important for the immune system. The video mentions that surgical removal of the thymus is a treatment for myasthenia gravis, suggesting that this may reduce the production of harmful antibodies, even in cases where the thymus gland does not appear to be directly involved in the disease process.

💡Acetylcholinesterase Inhibitors

Acetylcholinesterase inhibitors are a class of drugs that inhibit the enzyme acetylcholinesterase, which breaks down acetylcholine. The video explains that by inhibiting this enzyme, the concentration of acetylcholine around muscle cells is increased, which can help counteract the effects of antibodies that block the nicotinic acetylcholine receptors in myasthenia gravis.

💡Immunosuppressive Drugs

Immunosuppressive drugs are medications that reduce the activity of the immune system. The video mentions that myasthenia gravis is treated with drugs like prednisone, which are immunosuppressive, aiming to reduce the production of harmful antibodies that contribute to the disease's symptoms.

Highlights

Myasthenia gravis is an autoimmune disease that causes muscle weakness.

Patients may experience progressive weakness throughout the day and with repetitive movements.

The disease can cause double vision and drooping eyelids due to its effect on extraocular muscles.

Myasthenia gravis predominantly affects young women and older men, with an unclear cause for this age distribution.

Normal muscle contraction involves the release of acetylcholine at the neuromuscular junction.

Myasthenia gravis is a type II hypersensitivity disorder causing cytotoxic injury to muscle cells.

Autoantibodies in myasthenia gravis target nicotinic acetylcholine receptors on muscle cells.

Binding of antibodies to receptors prevents muscle contraction signals from the central nervous system.

Anti-acetylcholine receptor antibodies can activate the complement system, leading to inflammation and muscle cell destruction.

A minority of patients produce harmful antibodies that attack proteins inside muscle cells.

Myasthenia gravis can rarely present as a paraneoplastic syndrome related to underlying cancer.

Myasthenic crisis is a life-threatening condition that can affect breathing muscles.

Treatment for myasthenia gravis has reduced mortality, including the use of acetylcholinesterase inhibitors.

Immunosuppressive drugs like prednisone are used to reduce the production of harmful antibodies.

Surgical removal of the thymus is a common treatment, even in cases without identifiable thymus issues.

Helper T cells in the thymus may contribute to the production of antibodies against acetylcholine receptors.

Myasthenia gravis is characterized by antibodies targeting muscle cell receptors, leading to muscle weakness and potential cell destruction.

Transcripts

Myasthenia gravis, is a Latin expression that literally means “grave muscle weakness,”

which perfectly describes the weakness that happens when this autoimmune disease affects

the skeletal muscles.

People with myasthenia gravis might wake up feeling fine, but get progressively weaker

as the day goes on and by the end of the day they might feel very weak, sometimes even

getting weaker with repetitive movements like chopping vegetables.

Myasthenia gravis can affect the extraocular muscles, which control movement of the eye

as well as the eyelids, so individuals might have diplopia or double vision, as well as

ptosis, or drooping eyelids.

Myasthenia gravis preferentially affects young women in their 20s and 30s and older men in

their 60s and 70s, but the cause of this odd “bimodal” distribution of age-of-onset

isn’t quite clear.

To better understand myasthenia gravis, let’s review normal muscle contraction but at the

cellular level.

First you’ve got your motor neurons that release the neurotransmitter acetylcholine

at the neuromuscular junction, which then binds to nicotinic acetylcholine receptors

on muscle cell membranes.

Binding of acetylcholine to its receptor activates a chain reaction in the muscle cell that ultimately

results in muscle contraction.

But what happens in myasthenia gravis though?

Well remember that it’s an autoimmune disease, specifically one that’s categorized as a

type II hypersensitivity which causes cytotoxic injury meaning that it results in the lysis

or death of host cells, which is mediated by autoantibodies, which are antibodies that

are specific for our own cells or proteins.

Alright, so in this case, the patient’s B cells inappropriately make antibodies that

bind to nicotinic acetylcholine receptors on the muscle cells.

Once acetylcholine receptors are bound by the antibody, they are unable to bind to acetylcholine,

and therefore don’t respond to the “contract” signal from the central nervous system.

Anti-acetylcholine receptor antibodies can also activate the classical pathway of the

complement.

The complement system is a family of small proteins that work in an enzymatic cascade

to fight off bacterial infections.

The activation of complement causes inflammation and destruction of the muscle cells and reduces

the amount of acetylcholine receptors on the surface.

Now a minority of people with myasthenia gravis produce another type of harmful antibody called

muscle specific receptor tyrosine kinase antibodies, which attack proteins inside of muscle cells

instead of nicotinic acetylcholine receptors on the muscle cell surface, but they similarly

leads to destruction of healthy cells.

In very rare cases, myasthenia gravis can present as a paraneoplastic syndrome, which

means that an underlying cancer like bronchogenic carcinoma or thymic neoplasm (also known as

thymoma) generates an immune response which results in generation of autoantibodies.

In some cases, if certain muscles are affected, myasthenic patients can experience a myasthenic

crisis, which is a life-threatening manifestation of the disease.

An example of this might be a decreased function of the muscles that control breathing.

The good news is is that treatment has been able to reduce mortality from myasthenia gravis.

One type of medication is an acetylcholinesterase inhibitor, like neostigmine or pyridostigmine.

Acetylcholinesterase degrades acetylcholine, so acetylcholinesterase inhibitors stop acetylcholinesterase

from breaking down acetylcholine, which ends up increasing the concentration of acetylcholine

around muscle cells and helps counteract the effects of acetylcholine receptor antibodies.

Myasthenia gravis is also treated with immunosuppressive drugs (like prednisone), which reduce the

production of the harmful antibodies.

Finally, a lot of people with myasthenia gravis undergo surgical removal of the thymus.

This seems to reduce the muscle weakness symptoms even in people that don’t appear to have

any identifiable problems with the thymus gland itself.

It's possible that this is because helper T cells, which originate in the thymus, help

B cells make antibodies to the acetylcholine receptor.

Alright, as a quick review—myasthenia gravis is a type II hypersensitivity disorder where

the body produces antibodies that most commonly target nicotinic acetylcholine receptors on

the surface of muscle cells.

The antibodies block the receptors which means the signal to contract isn’t received.

Those antibodies also activate the complement pathway which leads to muscle cell destruction.

Myasthenia gravis preferentially affects young women or older men and commonly affects the

extraocular muscles leading to eyelid drooping or double vision, but it might affect any

skeletal muscle.

Thanks for watching, you can help support us by donating on patreon, subscribing to

our channel, or following us on social media.